

> **The Company**

MicroMed Technology, Inc. is a privately held company and the world leader in conceptualizing and developing miniaturized implantable ventricular assist device technology. The miniaturized DeBakey VAD® is the next generation of implantable mechanical ventricular support for advanced heart failure in adults and children. The DeBakey VAD® Child is the only VAD commercially released in the USA for pediatric patients.

> **Products**

The miniaturized DeBakey VAD® is the result of a collaboration of the world-renown medical-scientific team of Drs. Michael DeBakey and George Noon, Baylor College of Medicine, and NASA. It is intended for end-stage heart failure patients who can no longer provide necessary blood flow with their own heart.

The design addresses significant limitations of first generation systems, such as weight, size, noise, reliability and high rates of infection. It is highly durable, and is the size of a "C" cell battery and weighing only 4 ounces, 1/8 the weight of other implantable VADs in the US. The DeBakey VAD® is approved for use in two pivotal clinical trials. The DeBakey VAD® system has been awarded the CE mark for both Bridge to Transplant and Destination Therapy, which allows for commercial distribution in Europe. The DeBakey VAD® Child, already commercially released through an HDE in the US and CE mark approved, utilizes the same technology for support of pediatric patients.

> **Management and Medical Advisory Board**

TRAVIS E. BAUGH, Co-founder, President and Chief Executive Officer since January 2005, has been instrumental in the company's continued growth and success. Most recently, he served as executive vice president of Finance/Operations and CFO, where he was responsible for the production, finance and administrative activities of the company.

ROBERT J. BENKOWSKI, Senior VP of Engineering is co-inventor of the original NASA technology. He joined MicroMed in his current position in 1996. TIMOTHY R. PLACEK, Senior VP of Regulatory Affairs, Clinical Affairs and Quality Systems, has served the company since March 1998. BETTY S. RUSSELL, Chief Operating Officer and EVP, Worldwide Sales and Marketing, joined MicroMed in August 2002.

MICHAEL E. DEBAKEY, MD, is Chairman of the Advisory Board. Dr. DeBakey is recognized worldwide as a premier surgeon, medical inventor and innovator, gifted educator and international medical statesman. Today he serves as Chancellor Emeritus of Baylor College of Medicine and Director of both the DeBakey Heart Center of Baylor and the Methodist Hospital in Houston, Texas.

Dr. Michael DeBakey is internationally recognized as the most famous heart surgeon in the world and a living legend. Dr. DeBakey's accomplishments, from his innovations in open-heart surgery to his pioneering work in the field of telemedicine, include many of the greatest achievements in the history of medicine. He is credited with developing the Mobile Army Surgical Hospitals (M.A.S.H.) concepts for the military. Dr. DeBakey originally conceived the MicroMed DeBakey VAD® along with Dr. George P. Noon.

GEORGE P. NOON, MD, is Co-Principal Investigator and a Senior Attending Physician at Methodist Hospital in Houston, Texas. He is the Chief Director of Transplantation and Assist Devices in the Michael E. DeBakey Department of Surgery at Baylor College of Medicine. Dr. Noon was the first to implant the MicroMed DeBakey VAD® in European patients.

> **Opportunity**

Congestive heart failure (CHF) is the #1 killer in the US. Five million Americans have been diagnosed with CHF, and there are 550,000 new cases annually, constituting over 1 million hospital admissions, with a \$24.3 billion dollar price tag. This creates a compelling multi-billion dollar market.

Most insurance companies will now reimburse for the procedure, and the usual reimbursement by Medicare has risen up to \$200,000. There is strong CHF market opportunity, and a platform for acquisitions. Good patient outcomes are driving the support given by key opinion leaders. Over \$5 billion dollars has been invested by our world class group.

MicroMed's vision is to become the market leader in innovative treatments for CHF through internal product development and acquisitions. Using miniaturized next generation technology, the DeBakey BiVAD, the DeBakey VAD II, and the DeBakey Total Artificial Heart lead an incredibly innovative R&D pipeline, which generates clinical and commercial revenue.

The financial markets are risky. Investing is risky. Past performance does not guarantee future performance. The foregoing has been prepared solely for informational purposes and is not a solicitation, or an offer to buy or sell any security. Offering made by Offering Memorandum only. Opinions are based on historical research and data believed reliable, but there is no guarantee that future results will be profitable. This does not purport to be a complete analysis of the Portfolio Company. The author has relied on information provided by sources deemed to be reputable and although believed to be true, cannot guarantee the accuracy of such information. All claims made by this brochure should be verified by the reader. This brochure is not intended to directly or indirectly provide advice as to the value of any offer described herein, or as to the advisability of investing in such offer. Investing is not suitable for everyone; you should know and understand the risk before making a decision.